Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics to Merge with Genesoft Pharmaceuticals

NEW YORK, Nov. 18 (GenomeWeb News) - Genome Therapeutics said today that it would merge with privately held Genesoft Pharmaceuticals in an all-stock transaction expected to close in the first quarter of 2004.

The merged company, which will retain the name Genome Therapeutics until a new name is selected, will focus on the development and commercialization of new anti-infective therapeutics. The company expects to launch one such product, the antibiotic Factive (gemifloxacin mesylate tablets) in the summer of 2004.

David Singer, founder, chairman and CEO of Genesoft Pharmaceuticals, will become chairman of the new company.

Genome Therapeutics said it would issue around 28 million shares of its common stock to Genesoft shareholders, and assume debt of $24 million. Genome Therapeutics, which raised around $9 million in a common stock placement in September, said it plans to raise an additional $30 million to fund the merged company.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.